Angelo D. Michilli

Angelo D. Michilli

Internal Medicine

1296 North Avenue
2nd Floor Back Entrance B
New Rochelle, NY 10804

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 5 publications

Transcriptomic Analysis Reveals an NRF2-Mediated Redox and Metabolic Reprogramming in Sorafenib-Resistant Hepatocellular Carcinoma Cells.

Transcriptomic Analysis Reveals an NRF2-Mediated Redox and Metabolic Reprogramming in Sorafenib-Resistant Hepatocellular Carcinoma Cells.

Journal: Biotech (Basel (Switzerland))

Published: December 14, 2025

TG221: An Experimental Model for Liver Cancer Prevention and Treatment Approaches.

TG221: An Experimental Model for Liver Cancer Prevention and Treatment Approaches.

Journal: Biotech (Basel (Switzerland))

Published: December 01, 2025

Targeting metabolic vulnerabilities: REV-ERB agonist SR9009 potentiates sorafenib efficacy in liver cancer.

Targeting metabolic vulnerabilities: REV-ERB agonist SR9009 potentiates sorafenib efficacy in liver cancer.

Journal: Cell death discovery

Published: June 25, 2025

Circulating microRNAs as biomarkers for stratifying different phases of liver cancer progression and response to therapy.

Circulating microRNAs as biomarkers for stratifying different phases of liver cancer progression and response to therapy.

Journal: Scientific reports

Published: February 13, 2024

Monitoring Somatic Genetic Alterations in Circulating Cell-Free DNA/RNA of Patients with "Oncogene-Addicted" Advanced Lung Adenocarcinoma: A Real-World Clinical Study.

Monitoring Somatic Genetic Alterations in Circulating Cell-Free DNA/RNA of Patients with "Oncogene-Addicted" Advanced Lung Adenocarcinoma: A Real-World Clinical Study.

Journal: International journal of molecular sciences

Published: June 24, 2022

Showing 1-5 of 5

Last Updated: 09/26/2026